miRagen and Archemix will collaborate on conjugated aptamer-microRNA therapies.
miRagen and Archemix to jointly pursue R&D efforts and contribute resources under the agreement. It includes an exclusive option for miRagen to negotiate for exclusive rights, to further develop and commercialize certain aptamer-microRNA therapeutics generated during the collaboration.
Kenneth Bate, president and CEO of Archemix, said: “Combining aptamers and microRNA therapeutics has the potential to solve the intracellular delivery challenge for certain RNA-based therapeutic approaches.
“Intracellular delivery has been a key challenge for RNA modalities and we are excited about the potential of bringing together our expertise in aptamers with miRagen’s expertise in microRNA therapeutics to overcome this limitation and open further potential for RNA-based therapeutics, he added.